Enabling In Vivo Lentiviral Therapies: Manufacturing Strategies to Improve Purity, Scalability, and Clinical Readiness.
カートのアイテムが多すぎます
カートに追加できませんでした。
ウィッシュリストに追加できませんでした。
ほしい物リストの削除に失敗しました。
ポッドキャストのフォローに失敗しました
ポッドキャストのフォロー解除に失敗しました
Enabling In Vivo Lentiviral Therapies: Manufacturing Strategies to Improve Purity, Scalability, and Clinical Readiness.
-
ナレーター：
-
著者：
Lentiviral vectors are gaining momentum not just as ex vivo tools but as potential in vivo therapeutic platforms. But with that shift comes a number of manufacturing challenges, including higher doses, tighter control of impurities, greater batch consistency, and scalable processes to meet both clinical and commercial needs.
In this GEN Podcast, two experts from SK Pharmteco, a global CMO, address these challenges and lay out some best practices that guide the manufacture of lentiviral vectors with the requisite purity, robustness, and economic feasibility required for widespread clinical adoption.
Guest speakers:
Mardhani Aparajithan, Director of Manufacturing, Science and Technology, SK Pharmteco
Tatiana Nanda, PhD, CTO, Cell and Gene Therapy, SK Pharmteco
Moderator:
Kevin Davies, PhD, Editorial Director, GEN
Hosted on Acast. See acast.com/privacy for more information.